Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Inflammatory Carcinoma Clear all
Completed Phase 2 Interventional Results available

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

NCT00193206
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Fort Myers, Florida • Jacksonville, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Not applicable Interventional

Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

NCT01755130
View directory record Official record
Conditions
Breast Neoplasm, Inflammatory Breast Carcinoma
Interventions
Photoacoustic Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
20 Years to 85 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NCT00499122
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, NOV 002
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Miami, Florida • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Early Phase 1 Interventional Results available

Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer

NCT02415387
View directory record Official record
Conditions
Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
typhoid vaccine, Placebo
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

NCT01730833
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
Interventions
pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 6, 2026, 9:48 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
View directory record Official record
Conditions
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Atezolizumab, Cobimetinib, Eribulin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Xeloda (Capecitabine) and External Beam Radiation

NCT00916578
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation Therapy, Capecitabine
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 6, 2026, 9:48 AM EDT
Not listed Not applicable Interventional

Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors

NCT00336089
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Fatigue, Pain
Interventions
exercise intervention, educational intervention, complementary or alternative medicine procedure, fatigue assessment and management, management of therapy complications, pain therapy, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Clayton State University
Other
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Atlanta, Georgia • Morrow, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 6, 2026, 9:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

NCT04913064
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Questionnaire Administration, White Button Mushroom Extract
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional

Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

NCT00049114
View directory record Official record
Conditions
Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
doxorubicin hydrochloride, cyclophosphamide, tipifarnib, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 6, 2026, 9:48 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

NCT02971748
View directory record Official record
Conditions
Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Pembrolizumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 6, 2026, 9:48 AM EDT
Withdrawn Phase 2 Interventional

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

NCT05177796
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Panitumumab, Pembrolizumab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

NCT02389764
View directory record Official record
Conditions
Breast Cancer
Interventions
BIBF 1120, Phone Call
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 6, 2026, 9:48 AM EDT
Withdrawn Not applicable Interventional

Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study

NCT06057636
View directory record Official record
Conditions
Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms, Neoplasm Metastasis
Interventions
Self-Administered Hypnosis, Self-Administered White Noise Hypnosis
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

NCT00464646
View directory record Official record
Conditions
Breast Cancer
Interventions
Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Bevacizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
35
States / cities
Huntsville, Alabama • San Diego, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 6, 2026, 9:48 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00343512
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

NCT02658812
View directory record Official record
Conditions
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Inflammatory Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Talimogene Laherparepvec
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

NCT02892734
View directory record Official record
Conditions
HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 6, 2026, 9:48 AM EDT
Terminated Phase 2 Interventional Results available

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

NCT03872388
View directory record Official record
Conditions
Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Inflammatory Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Atorvastatin, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Gilbert, Arizona • Greeley, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional Results available

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

NCT01417286
View directory record Official record
Conditions
Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions
External beam radiation therapy
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 6, 2026, 9:48 AM EDT
Completed Phase 2 Interventional

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

NCT00111787
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Zion, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 6, 2026, 9:48 AM EDT